Evidence map›Paper›PMID 40630941›Full record

ReviewMolecular and clinical oncology2025

Role of

Abdul-Mohsen G Alhejaily, Omar Alhuzaim, Naji Aljohani, Doaa Alghamdi, Raneem O Salem

Abstract readReview
In one paragraph

Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abdul-Mohsen G AlhejailyAcademic Operations Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Kingdom of Saudi Arabia.
Omar AlhuzaimObesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Kingdom of Saudi Arabia.
Naji AljohaniObesity, Endocrine and Metabolism Center, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Kingdom of Saudi Arabia.
Doaa AlghamdiAnatomical Pathology Department, Pathology Department, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Kingdom of Saudi Arabia.
Raneem O SalemAcademic Operations Administration, King Fahad Medical City, Riyadh Second Health Cluster, Riyadh 11525, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present review provides a comprehensive analysis of the significance of telomerase reverse transcriptase (TERT) promoter mutations in the progression of anaplastic thyroid cancer (ATC). The significance of these mutations lies in their role in reactivating telomerase, and when combined with BRAF and RAS mutations, they contribute to heightened aggressiveness in ATC. The clinical implications of TERT promoter mutations were discussed, evaluating their potential role as prognostic biomarkers and targets for therapeutic intervention. The present review also emphasizes recent developments in our comprehension of TERT's role in the progression of ATC, offering insights that may guide future investigations focused on improving patient management for this condition.

Indexed as

anaplastic thyroid cancerBRAFmutationsoncogene activationtelomerase reactivationtelomerase reverse transcriptasetumorigenesis

Identifiers

PMID40630941
PMCPMC12235244

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.